Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
Oragenics, Inc. filed this Current Report on Form 8-K on April 18, 2024. The Company is incorporated in Florida and its common stock trades on the NYSE American under the symbol "OGEN". The filing addresses a regulatory notice received from the NYSE American regarding the Company's compliance with continued listing standards.
Key Financial Metrics
- Stockholders' Equity: $3.2 million as of December 31, 2023.
- Profitability Status: The Company reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2023.
- Revenue, Cash Flow, and Debt: The filing text does not provide specific values for revenue, cash flow, or debt levels.
Material Changes and Listing Status
The Company received notification from the NYSE American that it is no longer in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide. These sections require stockholders' equity of at least $4 million (for losses in three of the last four years) or $6 million (for losses in the last five years). Due to the reported equity of $3.2 million and five consecutive years of losses, the Company failed to meet these thresholds.
Consequently, the Company's common stock will continue to trade but will carry a ".BC" designation to indicate "below compliance" status.
Outlook, Management Commentary, and Risks
- Compliance Plan: The Company must submit a plan of compliance to the NYSE American by May 18, 2024. This plan must detail specific milestones, quarterly financial projections, and strategic initiatives to regain compliance by October 18, 2025.
- Management Intent: Management is committed to undertaking transactions to achieve compliance but noted there is no assurance that compliance will be achieved within the required timeframe.
- Risks of Delisting: If the Company fails to submit an acceptable plan or fails to regain compliance by the deadline, it faces delisting. Potential negative impacts include reduced liquidity and market price, diminished ability to raise equity financing, limitations on offering freely tradable securities, and impaired ability to provide equity incentives to employees.
- Operations: The notice has no immediate impact on ongoing business operations or SEC reporting requirements.
Investor Verification Checklist
- Verify the submission and acceptance of the compliance plan by the May 18, 2024 deadline.
- Monitor the ".BC" trading designation on the NYSE American.
- Review upcoming quarterly financial reports for progress toward the $4 million or $6 million equity thresholds.
- Assess the feasibility of the strategic initiatives or transactions proposed in the compliance plan.
- Track the Company's ability to raise capital given the current listing status.